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Abstract
Malignant bowel obstruction and intractable diarrhea in advanced cancer are common devastating syn-
dromes. Apart from disease specific, causative treatment in patients with longer prognosis, there is a
possibility of conservative, non-operative symptom management in terminal phase. A successful control of
intractable vomiting and diarrhea using octreotide in two advanced cancer patients was presented, with
guidance through steps of the management. Pathophysiologic vicious circle of the bowel obstruction and
diarrhoea was described and the management algorithm was proposed. Due to the gut hyposecreting
action, octreotide occurs to be a potent and essential drug in refractory vomiting or diarrhea.
Key words: malignant bowel obstruction, intractable diarrhea, octreotide
Adv. Pall. Med. 2009; 8, 4: 161–164
Address for correspondence: Tomasz Grądalski
Pain and Palliative Clinic, Chair of Internal Medicine and Gerontology
Jagiellonian University Collegium Medicum, Krakow, Poland
e-mail: tomgr@mp.pl
Advances in Palliative Medicine 2009, 8, 161–164
Copyright © 2009 Via Medica, ISSN 1898–3863
Introduction
In patients with end-stage disease malignant
bowel obstruction (MBO) is a quite common and
devastating complication, which worsens the qual-
ity of life and markedly shortens prognosis. Its fre-
quency ranges from 5% to 42% in advanced ovari-
an cancer and from 4% to 24% in advanced colorec-
tal cancer. It may be partial or complete and at
single or multiple sites; the small bowel is more
commonly involved than the large bowel (61% vs.
33% in over 20% of the patients both are involved).
Its pathological mechanisms may be benign (more
common in colorectal cancer, less in gynaecological
cancers), such as adhesions, post-irradiation bowel
damage, inflammatory bowel disease, hernia or
functional obstruction. Malignant causes are: ex-
trinsic, intrinsic or intraluminal gut occlusion and
neoplastic or paraneoplastic intestinal motility dis-
orders due to infiltration or neuropathy of mesen-
tery nerves or celiac plexus [1].
Typical clinical symptoms consist of nausea/vom-
iting and continuous abdominal pain (90% of pa-
tients, less severe in large bowel obstruction) which
induce colic pain due to gut ineffective motility (ap-
prox. 75% of patients). The most pronounced signs
are abdominal distension (periodically spontaneous-
ly resolving in partial MBO) and high-pitched peri-
stalsis or borborygmi [2]. Possible radiological in-
vestigations that may be performed in patients with
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symptoms and signs of MBO like plain/contrast ra-
diography or abdominal CT should be considered
only in patients who will benefit from surgery (good
performance and nutritional status, no previous
abdominal surgery or radiotherapy and acute sin-
gle mechanical obstruction). Surgical treatment —
which ought to be considered in every case — due
to high risk of mortality (9–40%) and complications
(9–90%) is not superior to conservative treatment
and may consist of laparotomy resection or gut by-
pass, endoscopy laser resection and endoscopy
stenting. In inoperable, vomiting and resistant to
pharmacological therapy patients venting proce-
dures [e.g. percutaneous endoscopically placed gas-
trostomy (PEG) tube] may be considered. To the
vast majority of terminal cancer patients drug ther-
apy is the only possible option. It focuses on relief
of nausea, vomiting and pain, sometimes may even
temporally reverse the MBO signs.
Diarrhoea in advanced cancer relates to approx.
10% of patients can be caused by drugs (laxatives,
antibiotics, antacids or chemotherapy), radiothera-
py, oncological surgery (e.g. restorative proctocolec-
tomy) gastrointestinal tumours, infection, inflam-
mation, malabsorption or incorrect diet. Particular-
ly in older patients “diarrhea” can also be a sign of
the overflow fecal incontinence caused by fecal im-
paction. Apart from disease specific (causal) man-
agement, treatment usually includes opioids (mor-
phine or loperamide), pancreatic enzyme replace-
ment or probiotics. In intractable or refractory diar-
rhoea (ID) gut hypersecretion can play a significant
role [3]. This excessive secretion can be caused by
the damage to the intestinal mucosa including loss
of intestinal epithelium, superficial necrosis, and in-
flammation of the bowel wall (e.g. due to chemo-
therapy) the presence of fistulas or neuroendocrine
gastrointestinal tumors (carcinoids or endocrine
pancreatic tumors) or paraneoplastic stimulation of
the gut enzymes [4–6].
The aim of this study is to present two cases of
successful management of MBO and ID in terminal
cancer patients using somatostatin analogue.
Case 1
A 75 year old man, with three-year history of
colon cancer (adenocarcinoma tubulare) was ad-
mitted to the hospice. He complained of severe un-
restrained vomiting (up to 2 litres a day), weakness,
anorexia, abdominal pain and sleep disturbances.
Laparotomy revealed relapse of the disease with
bowel obstruction (regional 25 cm infiltration of
sigmoid spreading into small intestine and retro-
peritoneal space). Performed surgical treatment (par-
tial small bowel resection and colostomy) had
brought no relief. Afterwards gastro-entero anas-
tomosis also had not alleviated the symptoms. On
the contrary his nausea and vomiting had being
more and more severe in time. Due to his ileus he
became bed bound and depressive and his social
contact was scarce. During hospice care he did not
respond to more than 7 days trial of dexametha-
sone (8 mg a day i.v.) with metoclopramide. Halo-
peridol and levomepromazine benefit was of minor
importance too, with aggravation of depression and
consciousness disturbances. Hyoscine butybromide
(up to 180 mg a day) was completely inefficient
with huge discomfort of dry mouth and mental de-
terioration. A trial of octreotide was suggested and
his vomiting diminished immediately and was con-
trolled on 0,3 mg a day. His sc daily morphine de-
mand decreased from 60 to 30 mg. Attempt of
octreotide withdrawal caused symptoms recurrence.
He was stable for seven months, walking with assis-
tance, with good appetite, enteral diet and with
mood improvement, until peaceful death preceded
by slow general deterioration.
Case 2
A 82 year old woman with advanced cervical can-
cer after palliative colostomy was suffering of a huge
diarrhea because of malignant bowel obstruction
symptoms. It made administering of her colostomy
sacks almost impossible. In subsequence there was a
huge skin irritation, pruritus and the risk of electro-
lytes loss. Odour and shame took effect in avoiding
of social contact and exacerbated depression. On
admission: bed bound, with extensive scorching and
burning red inflammatory skin irritation around the
colostomy. She was not hypercalcemic. Her diarrhea
was not controlled on high doses of pancreatic en-
zymes, loperamide, hyoscine butybromide and mor-
phine, with additional notable adverse symptoms as
dry mouth. Similarly a trial of steroids did not cause
improvement. Octreotide at a starting dose of 0.1
mg a day (in divided doses) was administered, and
titrated to 0.3 mg a day, with eventual diarrhea as-
sessment. It enabled colostomy sack administration
and skin irritations healing. In consequence of this
treatment, the patient’s psychological condition and
social contacts improved and occupational therapy
became possible. A trial of octreotide withdrawal
caused diarrhea recurrence. She remained stable for
two months and died in comfort.
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Pathophysiology of MBO and ID
The most distressing symptoms of MBO are vom-
iting, colic or continuous pain; in ID: colic pain and
devastating frequent bowel movements. The in-
crease of bowel secretion and contraction seems to
play the crucial role both in the vicious circle of
MBO and ID (Fig. 1).
MBO drug therapy comprising analgetics, anti-
emetics, and antisecretory drugs without using a
nasogastric tube was first described by Mary Baines
et al. in 1985 [7]. The drugs of choice vary to a
certain extent between countries and different cen-
ters, based on clinical experience, drug availability,
cost and fashion. Medication should be tailored to
each patient with regard to both the drugs to be
administered and the route of administration. In
resistant MBO to anticholinergics a trial of octreotide
can be a valuable option (Fig. 2).
ID therapy
Diarrhea is a symptom. When possible, the un-
derlying disorder should be treated, but symptom-
atic treatment is often necessary. Traditional ID
symptomatic management has focused on the use
of nonspecific therapy such as atropine, loperam-
ide, codeine, and the opium mixture. Alternative
nonspecific approaches include anticholinergics,
antispasmodics, and adsorbent agents preparations.
Opioids exert their antidiarrheal activity on gas-
trointestinal cells by their agonistic effects on opio-
id receptors, thus decreasing peristaltic movements
and increasing absorption. However, although opi-
oids are currently considered as gold standard for
ID in cancer patients, their effectiveness in control-
Figure 1. The importance of bowel secretion and
contraction in MBO/ID pathomechanisms
Figure 2. MBO conservative management diagram
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ling it can be insufficient. Additionally, chronic or
high-dose opioid treatment may cause serious side
effects, e.g. loperamide-induced paralytic ileus,
which makes close monitoring of patients receiving
this antidiarrheal treatment mandatory. The soma-
tostatin can exert its antidiarrheal actions by multi-
ple mechanisms.
Octreotide is a synthetic analogue of somatosta-
tin with a longer duration of action. It inhibits the
release of growth hormone, TSH, prolactin and ACTH,
the secretion of insulin, glucagon, gastrin and other
peptides of the gastro-enteropancreatic system, re-
ducing splanchnic blood flow, portal blood flow,
gastro-intestinal motility, gastric, pancreatic and small
bowel secretion, and increasing water/electrolyte
absorption. In patients with cancer and inoperable
bowel obstruction, octreotide rapidly improves symp-
toms in ≥ 75% of patients. In hormone-secreting
tumours, octreotide improves symptoms by inhibit-
ing hormone secretion, e.g.: 5HT in carcinoid (im-
proving flushing and diarrhoea) VIP in VIPomas (im-
proving diarrhoea) glucagon in glucagonomas (im-
proving rash and diarrhoea). In refractory secretory
diarrhoea it is known to enhance water and sodium
absorption from the small intestine, it inhibits chlo-
ride secretion in the colon and prolongs small intes-
tine transit [8]. Octreotide has a direct anticancer
effect on solid tumours of the gastro-intestinal tract
thus can prolong survival. It is poorly absorbed after
oral administration. After subcutaneous injection its
duration of action can extend up to 12 hours so it
should be given not less frequently than twice a day.
The dose should be titrated according to the effect.
There are 2-drug compatibility data for octreotide in
0.9% saline with diamorphine, haloperidol, hyoscine
butylbromide, midazolam, morphine sulphate and
ondansetron. Incompatibility may occur with dex-
amethasone or levomepromazine [9]. A long-acting
formulation (LAR) has been designed to provide long-
term controlled release after a singular intramuscu-
lar injection. Most side effects encountered with oct-
reotide are either local (pain, redness or swelling) or
gastrointestinal (anorexia, nausea, vomiting, abdom-
inal cramp-like pain). Adverse endocrinological ef-
fects are rare. Due to the high acquisition costs (0.1
mg ampoule = approx. 30 PLN comparable with for
example hyoscine butylbromide: 20 mg ampoule =
approx. 1 PLN), the cost effectiveness of prescribing
octreotide must be considered before commencing
therapy [5].
In the case 1 of MBO, both surgical and conser-
vative management failed — octreotide due to res-
toration of the gut passage and symptom with-
drawal — gave the patient seven months of fairly
normal life. In the case 2, ID resistant to causal
treatment, irresponsive to opioid, pancreatic enzyme
and probiotic therapy suggested excessive fluid se-
cretion. The enrollment of octreotide gave the pa-
tient not only restoration of the normal bowel move-
ment and possibility to skin lesion healing, but also
improved her mood and diminished social isolation.
Octreotide occured the valuable option in the man-
agement of drug resistant MBO and ID.
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